Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany
We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban’s ENGAGE-AF, dabigatran’s RE-LY, riv...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2015
|
| In: |
BioMed research international
|
| ISSN: | 2314-6141 |
| DOI: | 10.1155/2015/876923 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1155/2015/876923 Verlag, kostenfrei, Volltext: https://www.hindawi.com/journals/bmri/2015/876923/abs/ 
|
| Author Notes: | Martin Krejczy, Job Harenberg, Martin Wehling, Konrad Obermann, Gregory Y.H. Lip |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1559128267 | ||
| 003 | DE-627 | ||
| 005 | 20230428071159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170530s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2015/876923 |2 doi | |
| 035 | |a (DE-627)1559128267 | ||
| 035 | |a (DE-576)489128262 | ||
| 035 | |a (DE-599)BSZ489128262 | ||
| 035 | |a (OCoLC)1340975722 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Krejczy, Martin |d 1987- |e VerfasserIn |0 (DE-588)1068281901 |0 (DE-627)820016349 |0 (DE-576)427604788 |4 aut | |
| 245 | 1 | 0 | |a Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany |c Martin Krejczy, Job Harenberg, Martin Wehling, Konrad Obermann, Gregory Y.H. Lip |
| 264 | 1 | |c 2015 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 30.05.2017 | ||
| 520 | |a We compared the cost-utility analysis for edoxaban at both doses with that of dabigatran at both doses, rivaroxaban, and apixaban (non vitamin K antagonist oral anticoagulants, NOAC) in a German population. Data of clinical outcome events were taken from edoxaban’s ENGAGE-AF, dabigatran’s RE-LY, rivaroxaban’s ROCKET, and apixaban’s ARISTOTLE trials. The base-case analyses of a 65-year-old person with a CHADS2 score >1 gained 0.17 and 0.21 quality-adjusted life years over warfarin for 30 mg od and 60 mg od edoxaban, respectively. The incremental cost-effectiveness ratio was 50.000 and 68.000 euro per quality-adjusted life years for the higher and lower dose of edoxaban (Monte Carlo simulation). These findings were also similar to those for apixaban and more cost-effective than the other NOAC regimens. The current market costs for direct oral anticoagulants are high in relation to the quality of life gained from a German public health care insurance perspective. The willingness-to-pay threshold was lowest for 60 mg edoxaban compared to all direct oral anticoagulants and for 30 mg edoxaban compared to dabigatran and rivaroxaban. | ||
| 700 | 1 | |a Harenberg, Job |d 1950- |e VerfasserIn |0 (DE-588)108825507 |0 (DE-627)655891498 |0 (DE-576)339563745 |4 aut | |
| 700 | 1 | |a Wehling, Martin |d 1957- |e VerfasserIn |0 (DE-588)129939331 |0 (DE-627)484463152 |0 (DE-576)297912577 |4 aut | |
| 700 | 1 | |a Obermann, Konrad |e VerfasserIn |0 (DE-588)1045404373 |0 (DE-627)774501650 |0 (DE-576)399004475 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BioMed research international |d [Hoboken, NJ] : Wiley, 2013 |g (2015) Article ID e876923, 13 Seiten |h Online-Ressource |w (DE-627)734738145 |w (DE-600)2698540-8 |w (DE-576)377910473 |x 2314-6141 |7 nnas |a Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany |
| 773 | 1 | 8 | |g year:2015 |g extent:13 |a Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2015/876923 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.hindawi.com/journals/bmri/2015/876923/abs/ |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170530 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 1045404373 |a Obermann, Konrad |m 1045404373:Obermann, Konrad |d 60000 |d 65300 |e 60000PO1045404373 |e 65300PO1045404373 |k 0/60000/ |k 1/60000/65300/ |p 4 | ||
| 998 | |g 129939331 |a Wehling, Martin |m 129939331:Wehling, Martin |d 60000 |d 65400 |e 60000PW129939331 |e 65400PW129939331 |k 0/60000/ |k 1/60000/65400/ |p 3 | ||
| 998 | |g 108825507 |a Harenberg, Job |m 108825507:Harenberg, Job |d 60000 |d 65400 |e 60000PH108825507 |e 65400PH108825507 |k 0/60000/ |k 1/60000/65400/ |p 2 | ||
| 999 | |a KXP-PPN1559128267 |e 2970475375 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1559128267","physDesc":[{"extent":"13 S."}],"origin":[{"dateIssuedDisp":"2015","dateIssuedKey":"2015"}],"relHost":[{"pubHistory":["2013 -"],"origin":[{"publisher":"Wiley ; Hindawi","publisherPlace":"[Hoboken, NJ] ; New York [u.a.]","dateIssuedKey":"2024","dateIssuedDisp":"2024-"}],"title":[{"title":"BioMed research international","title_sort":"BioMed research international"}],"part":{"year":"2015","text":"(2015) Article ID e876923, 13 Seiten","extent":"13"},"id":{"zdb":["2698540-8"],"doi":["10.1155/2738"],"eki":["734738145"],"issn":["2314-6141"]},"note":["Gesehen am 13.01.25"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"734738145","physDesc":[{"extent":"Online-Ressource"}],"disp":"Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in GermanyBioMed research international"}],"person":[{"display":"Krejczy, Martin","role":"aut","given":"Martin","family":"Krejczy"},{"display":"Harenberg, Job","role":"aut","given":"Job","family":"Harenberg"},{"family":"Wehling","role":"aut","given":"Martin","display":"Wehling, Martin"},{"display":"Obermann, Konrad","family":"Obermann","role":"aut","given":"Konrad"}],"title":[{"title_sort":"Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany","title":"Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 30.05.2017"],"name":{"displayForm":["Martin Krejczy, Job Harenberg, Martin Wehling, Konrad Obermann, Gregory Y.H. Lip"]},"id":{"doi":["10.1155/2015/876923"],"eki":["1559128267"]}} | ||
| SRT | |a KREJCZYMARCOSTEFFECT2015 | ||